Fresenius Medical Care AG resolves share buyback program with a total volume of EUR 1 billion in tranches within 2 years
|
EQS-Ad-hoc: Fresenius Medical Care AG / Key word(s): Share Buyback Bad Homburg, June 17, 2025 – Fresenius Medical Care AG (“Company”) has decided to conduct a share buyback program with a volume of EUR 1 billion (excluding ancillary costs) in tranches within two years after the start of the program. The execution of the share buyback program in tranches is planned to commence in the second half of 2025. The shares shall be acquired on the stock exchange and are to be predominantly redeemed and, to a significantly lesser extent, may be used for allocations under incentive-based compensation plans. The share buyback program is based on the authorization to purchase and use treasury shares granted by the Company’s Annual General Meeting on May 20, 2021. Continuation of the share buyback program beyond the current authorization is subject to the necessary resolutions of the Company’s bodies.
End of Inside Information
17-Jun-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Fresenius Medical Care AG |
| Else-Kröner-Straße 1 | |
| 61352 Bad Homburg | |
| Germany | |
| Phone: | +49 (0) 6172- 609 2525 |
| Fax: | +49 (0) 6172- 609 2301 |
| E-mail: | ir@freseniusmedicalcare.com |
| Internet: | www.freseniusmedicalcare.com |
| ISIN: | DE0005785802 |
| WKN: | 578580 |
| Indices: | DAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; NYSE, Luxembourg Stock Exchange |
| EQS News ID: | 2156174 |
| End of Announcement | EQS News Service |
|
|
2156174 17-Jun-2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.